Search

Alzheimer's Association Supports First Human Trials of NTRX-07

NeuroTherapia has received funding from the Alzheimer's Association to support the first human trials of NTRX-07, a novel new therapy targeted towards inflammation in the brain and nervous system.


The trial, set to begin in October, 2019, will study the pharmacology and safety of NTRX-07 in normal volunteers. The company plans to follow this study with a safety study in patients given NTRX-07 for up to one month.


NTRX-07 blocks neuro-inflammation, which has been identified as a cause of injury to the brain in Alzheimer's disease and other neurodegenerative diseases. Neuro-inflammation also plays an important role in the development of chronic neuropathic pain which may occur after injury or treatment with some chemotherapy agents.

50 views

Recent Posts

See All

PO Box 351

1500 Chagrin River Rd.

Gates Mills, OH  44040

216-870-7969

©2019 by NeuroTherapia, Inc.